Table 1.

Number of votes received for each of the initial 12 “Areas for development” in multiple sclerosis care as identified by the MS in the 21st Century Steering Group

Area for development	Number of votes (%); n = 13, six votes per person
Commitment to research	16 (20.5)
Regulatory body education	12 (15.4)
New endpoints in clinical trials	11 (14.1)
Healthcare and social care; personalized care	9 (11.5)
More therapy options	9 (11.5)
MS centers of excellence	7 (9)
Informed, shared decision-making	4 (5.1)
Better communication between stakeholders	3 (3.8)
Cost and reimbursement	3 (3.8)
Drugs with better risk:benefit profiles	2 (2.6)
Early treatment	1 (1.3)
Patient engagement and enablement	1 (1.3)

Each voting group member had a total of six votes. Multiple votes for a single topic were allowed. The group that attended the second meeting and were eligible to vote included eight neurologists, one pharmacoepidemiologist/pharmacoeconomist, three MS group/society members, and one consultant with a long-standing relationship with the MS community in Canada